0.037
23.33%
+0.007
Nls Pharmaceutics Ag Borsa (NLSPW) Ultime notizie
NLS Pharmaceutics (NASDAQ:NLSP) Stock Price Up 9.8% - Defense World
Defense World
NLS Pharmaceutics Extends Loan Maturity Date - TipRanks.com - TipRanks
TipRanks
NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the ... - The Globe and Mail
The Globe and Mail
NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice - The Globe and Mail
The Globe and Mail
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions - The Globe and Mail
The Globe and Mail
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing - Yahoo Finance
Yahoo Finance
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering - AccessWire
AccessWire
NLS Pharmaceutics Extends Loan Maturity Date - TipRanks.com - TipRanks
TipRanks
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist ... - AccessWire
AccessWire
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq - Yahoo Finance
Yahoo Finance
Notice of Deficiency with Nasdaq Continued Listing Requirements - Yahoo Finance
Yahoo Finance
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual ... - Yahoo Finance
Yahoo Finance
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification - Yahoo Finance
Yahoo Finance
NLS Pharmaceutics Announces Company Update on Strategic Partnerships - Yahoo Finance
Yahoo Finance
FDA reviews protocol of NLS Pharmaceutics' study of Mazindol ER - Clinical Trials Arena
Clinical Trials Arena
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of ... - SEC.gov
SEC.gov
NLS Pharmaceutics Announces Company Update Webcast - AccessWire
AccessWire
FDA approves NLS' narcolepsy therapy Phase III programme - Clinical Trials Arena
Clinical Trials Arena
NLS Pharmaceutics to Present at the 35th Annual Roth Conference - The Globe and Mail
The Globe and Mail
NLS Pharmaceutics CEO Issues Letter to Shareholders - December 22, 2022 - BioSpace
BioSpace
NLS Pharmaceutics Announces Purchase Agreement with BVF Partners L.P. to Raise Aggregate Gross Proceeds of up ... - AccessWire
AccessWire
NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the ... - The Globe and Mail
The Globe and Mail
NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex ... - PR Newswire
PR Newswire
NLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Offering - PR Newswire
PR Newswire
NLS Pharmaceutics Announces the Completion of the Merger between NLS Pharma Ltd., NLS-1 Pharma Ltd. and NLS ... - GlobeNewswire
GlobeNewswire
Capitalizzazione:
|
Volume (24 ore):